Genor Biopharma Holdings (HKG:6998) has decided to postpone its extraordinary general meeting to Feb. 19 from Feb. 13, a Tuesday bourse filing said.
The delay was attributed to the company requiring additional time to determine certain information related to the company's proposal to change its auditor from PricewaterhouseCoopers to Ernst & Young.